{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5e8308ce6b0fef1a38c4a215/66fe6af5e43e42d9173f97c1?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"“How I treat” a patient with DNMT3A-mutated AML in remission post intensive chemotherapy","description":"<p>The AML Hub was pleased to speak with Cristina Papayannidis, Universitaria di Bologna, Bologna, IT. We asked, How do you treat a patient with <em>DNMT3A</em>-mutated acute myeloid leukemia (AML) in remission post intensive chemotherapy?</p><p><em>This educational resource is independently supported by Bristol Myers Squibb. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.</em>&nbsp;</p>","author_name":"Scientific Education Support"}